Key Points
- CEO Daniel Patrick O'day sold 10,000 Gilead shares on Dec. 29 at an average price of $124.83 for $1,248,300, reducing his direct stake to 566,698 shares (a 1.73% ownership decrease) per an SEC filing.
- The Dec. 29 sale is part of a recent pattern of insider selling—he also sold 10,000 shares on Nov. 28 and 10,000 on Oct. 28, totaling 30,000 shares sold in the past few months.
- Separately, Gilead recently beat quarterly EPS and revenue estimates (EPS $2.47 vs. $2.16 expected), set FY2025 guidance of $8.05–$8.25 EPS, and pays a $0.79 quarterly dividend (about a 2.6% yield).
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares of the company's stock, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Daniel Patrick O'day also recently made the following trade(s):
- On Friday, November 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00.
- On Tuesday, October 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00.
Gilead Sciences Stock Performance
Shares of GILD opened at $123.18 on Wednesday. The company has a market cap of $152.83 billion, a price-to-earnings ratio of 19.10, a P/E/G ratio of 0.69 and a beta of 0.32. The business's fifty day simple moving average is $122.97 and its two-hundred day simple moving average is $116.89. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The company's quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences's payout ratio is currently 48.99%.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Gilead Sciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, December 20th. Citigroup raised their price target on Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research note on Wednesday, October 8th. UBS Group upgraded Gilead Sciences to a "hold" rating in a research report on Thursday, December 4th. Argus raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Tuesday, November 4th. Finally, HSBC boosted their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $131.68.
Check Out Our Latest Report on Gilead Sciences
Institutional Trading of Gilead Sciences
Hedge funds have recently bought and sold shares of the stock. Trivium Point Advisory LLC raised its stake in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company's stock worth $813,000 after buying an additional 83 shares during the period. Binnacle Investments Inc raised its stake in Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company's stock worth $87,000 after acquiring an additional 83 shares during the period. Rothschild Investment LLC raised its stake in Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock worth $503,000 after acquiring an additional 84 shares during the period. Hemington Wealth Management lifted its holdings in Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company's stock valued at $110,000 after purchasing an additional 85 shares in the last quarter. Finally, Ignite Planners LLC boosted its position in shares of Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock worth $880,000 after purchasing an additional 86 shares during the period. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
